Investment Thesis
Lifevantage demonstrates solid revenue growth of 14.2% YoY and maintains an exceptional gross margin of 77.4%, supported by a fortress balance sheet with zero debt and positive free cash flow. However, severe margin compression (77.4% gross to 3.2% operating) raises material concerns about cost structure and operational efficiency, resulting in anemic 2.7% net margins that limit profitability despite strong top-line performance.
Strengths
- Revenue growth of 14.2% YoY shows market traction
- Exceptional gross margin of 77.4% indicates strong product economics
- Zero long-term debt with debt/equity ratio of 0.00x provides financial flexibility
- Positive free cash flow of $2.9M demonstrates cash generation capability
- Strong liquidity position with 1.96x current ratio and $12.5M cash reserve
- Positive ROE of 11.4% and ROA of 6.1% show capital productivity
Risks
- Severe 44.2 percentage point margin compression (gross to operating) indicates unsustainable cost structure or excessive operating expenses
- Net income of only $3.8M on $140.2M revenue (2.7% margin) suggests profitability concerns despite scale
- Operating cash flow of $5.5M leaves limited cushion for growth investments or shareholder returns
- Operating margin of 3.2% is dangerously thin and vulnerable to any revenue decline
Key Metrics to Watch
- Operating margin trend - critical to determine if 3.2% can expand toward industry norms
- SG&A and R&D spending as percentage of revenue - understand drivers of the margin compression
- Free cash flow conversion - monitor if FCF margin can improve beyond 2.1%
Financial Metrics
Revenue
140.2M
Net Income
3.8M
EPS (Diluted)
$0.30
Free Cash Flow
2.9M
Total Assets
62.1M
Cash
12.5M
Profitability Ratios
Gross Margin
77.4%
Operating Margin
3.2%
Net Margin
2.7%
ROE
11.4%
ROA
6.1%
FCF Margin
2.1%
Balance Sheet & Liquidity
Current Ratio
1.96x
Quick Ratio
1.04x
Debt/Equity
0.00x
Debt/Assets
46.3%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:37:38.158841 |
Data as of: 2026-03-31 |
Powered by Claude AI